BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 19037107)

  • 1. Mannose 6-phosphate/insulin-like growth factor 2 receptor limits cell invasion by controlling alphaVbeta3 integrin expression and proteolytic processing of urokinase-type plasminogen activator receptor.
    Schiller HB; Szekeres A; Binder BR; Stockinger H; Leksa V
    Mol Biol Cell; 2009 Feb; 20(3):745-56. PubMed ID: 19037107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble M6P/IGF2R released by TACE controls angiogenesis via blocking plasminogen activation.
    Leksa V; Loewe R; Binder B; Schiller HB; Eckerstorfer P; Forster F; Soler-Cardona A; Ondrovicová G; Kutejová E; Steinhuber E; Breuss J; Drach J; Petzelbauer P; Binder BR; Stockinger H
    Circ Res; 2011 Mar; 108(6):676-85. PubMed ID: 21273553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biotin-Chasing Assay to Evaluate uPAR Stability and Cleavage on the Surface of Cells.
    Leksa V; Schiller HB; Stockinger H
    Methods Mol Biol; 2018; 1731():39-47. PubMed ID: 29318541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissecting mannose 6-phosphate-insulin-like growth factor 2 receptor complexes that control activation and uptake of plasminogen in cells.
    Leksa V; Pfisterer K; Ondrovičová G; Binder B; Lakatošová S; Donner C; Schiller HB; Zwirzitz A; Mrvová K; Pevala V; Kutejová E; Stockinger H
    J Biol Chem; 2012 Jun; 287(27):22450-62. PubMed ID: 22613725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding of urokinase-type plasminogen activator receptor (uPAR) to the mannose 6-phosphate/insulin-like growth factor II receptor: contrasting interactions of full-length and soluble forms of uPAR.
    Kreiling JL; Byrd JC; Deisz RJ; Mizukami IF; Todd RF; MacDonald RG
    J Biol Chem; 2003 Jun; 278(23):20628-37. PubMed ID: 12665524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation.
    Tarui T; Akakura N; Majumdar M; Andronicos N; Takagi J; Mazar AP; Bdeir K; Kuo A; Yarovoi SV; Cines DB; Takada Y
    Thromb Haemost; 2006 Mar; 95(3):524-34. PubMed ID: 16525582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IGF-II/mannose 6-phosphate receptor activation induces metalloproteinase-9 matrix activity and increases plasminogen activator expression in H9c2 cardiomyoblast cells.
    Chang MH; Kuo WW; Chen RJ; Lu MC; Tsai FJ; Kuo WH; Chen LY; Wu WJ; Huang CY; Chu CH
    J Mol Endocrinol; 2008 Aug; 41(2):65-74. PubMed ID: 18495691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
    Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
    BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.
    Liu D; Zhou D; Wang B; Knabe WE; Meroueh SO
    ACS Chem Biol; 2015 Jun; 10(6):1521-34. PubMed ID: 25671694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration.
    Yebra M; Parry GC; Strömblad S; Mackman N; Rosenberg S; Mueller BM; Cheresh DA
    J Biol Chem; 1996 Nov; 271(46):29393-9. PubMed ID: 8910604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of urokinase plasminogen activator/plasmin-mediated invasion of melanoma cells by the integrin vitronectin receptor alphaVbeta3.
    Khatib AM; Nip J; Fallavollita L; Lehmann M; Jensen G; Brodt P
    Int J Cancer; 2001 Feb; 91(3):300-8. PubMed ID: 11169951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Signaling through urokinase and urokinase receptor in lung cancer cells requires interactions with beta1 integrins.
    Tang CH; Hill ML; Brumwell AN; Chapman HA; Wei Y
    J Cell Sci; 2008 Nov; 121(Pt 22):3747-56. PubMed ID: 18940913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasminogen activator inhibitors regulate cell adhesion through a uPAR-dependent mechanism.
    Czekay RP; Loskutoff DJ
    J Cell Physiol; 2009 Sep; 220(3):655-63. PubMed ID: 19472211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration.
    Duriseti S; Goetz DH; Hostetter DR; LeBeau AM; Wei Y; Craik CS
    J Biol Chem; 2010 Aug; 285(35):26878-26888. PubMed ID: 20501655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins.
    Czekay RP; Aertgeerts K; Curriden SA; Loskutoff DJ
    J Cell Biol; 2003 Mar; 160(5):781-91. PubMed ID: 12615913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ascites induces modulation of alpha6beta1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma.
    Ahmed N; Riley C; Oliva K; Rice G; Quinn M
    Br J Cancer; 2005 Apr; 92(8):1475-85. PubMed ID: 15798771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single amino acid substitutions in the chemotactic sequence of urokinase receptor modulate cell migration and invasion.
    Bifulco K; Longanesi-Cattani I; Franco P; Pavone V; Mugione P; Di Carluccio G; Masucci MT; Arra C; Pirozzi G; Stoppelli MP; Carriero MV
    PLoS One; 2012; 7(9):e44806. PubMed ID: 23049759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
    Yin S; Lockett J; Meng Y; Biliran H; Blouse GE; Li X; Reddy N; Zhao Z; Lin X; Anagli J; Cher ML; Sheng S
    Cancer Res; 2006 Apr; 66(8):4173-81. PubMed ID: 16618739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
    Pulukuri SM; Gondi CS; Lakka SS; Jutla A; Estes N; Gujrati M; Rao JS
    J Biol Chem; 2005 Oct; 280(43):36529-40. PubMed ID: 16127174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Participation of the urokinase-type plasminogen activator receptor (uPAR) in neutrophil transendothelial migration.
    Pliyev BK; Antonova OA; Menshikov M
    Mol Immunol; 2011 May; 48(9-10):1168-77. PubMed ID: 21470685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.